A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration

To evaluate whether topical acrizanib (LHA510), a small-molecule vascular endothelial growth factor receptor inhibitor, could suppress the need for anti–vascular endothelial growth factor therapy over a 12-week period in patients with neovascular age-related macular degeneration. A phase 2 multicent...

Celý popis

Podrobná bibliografia

Vydané v:	American journal of ophthalmology Ročník 239; s. 180 - 189
Hlavní autori:	Poor, Stephen H., Weissgerber, Georges, Adams, Christopher M., Bhatt, Harit, Browning, David J., Chastain, James, Ciulla, Thomas A., Ferriere, Michael, Gedif, Kinfemichael, Glazer, Louis C., Joondeph, Brian C., Normand, Guillaume, Sheth, Veeral, Watters, Christie, Grosskreutz, Cynthia L.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 01.07.2022 Elsevier Limited
Predmet:	Antibodies Clinical trials Diabetic retinopathy Drug dosages Immunoglobulins Kinases Laboratories Macular degeneration Monoclonal antibodies Patients Vascular endothelial growth factor United States > US
ISSN:	0002-9394, 1879-1891, 1879-1891
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!